ANI Pharmaceuticals (ANIP)

[Just the facts maam]

Jeff, I agree with you and the other that we should be trading much higher. Small correction, ANIP expects Corti drugs to generate upwards of $200 million in cash flow. Assuming this is based on the 50% target of Acthar sales and at a 25% discount, as mentioned in earlier presentations, you are probably looking at an increase in revenue of over $450 million.

As for Libigel, or what ever it will be called. It will be interesting to see if anything is presented at the American Heart Association (AHA) Council on Hypertension 2017 Scientific Sessions to be held at the Hyatt Regency San Francisco, September 14-17, San Francisco, CA.

Scientific Meetings

JMHO